T1	p 74 140	patients with chemotherapy-induced painful peripheral neuropathy :
T2	p 465 686	at 8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 . Study
T3	p 701 722	completed July 2012 .
T4	p 784 792	patients
T5	p 920 959	patients have grade 1 or higher sensory
T6	p 2297 2304	painful
T7	i 16 26	duloxetine
T8	i 316 326	duloxetine
T9	i 430 448	placebo-controlled
T10	i 827 877	duloxetine followed by placebo or placebo followed
T11	i 881 891	duloxetine
T12	i 1133 1187	paclitaxel , other taxane , or oxaliplatin treatment .
T13	i 1244 1259	1 capsule daily
T14	i 1270 1300	30 mg of duloxetine or placebo
T15	i 1354 1381	duloxetine or placebo daily
T16	i 1501 1508	placebo
T17	i 1942 1949	placebo
T18	i 2065 2072	placebo
T19	i 2156 2166	duloxetine
T20	i 2204 2211	placebo
T21	i 2386 2393	placebo
T22	o 30 67	pain , function , and quality of life
T23	o 234 276	chemotherapy-induced peripheral neuropathy
T24	o 354 367	pain severity
T25	o 952 970	sensory neuropathy
T26	o 1024 1038	Adverse Events
T27	o 1099 1124	chemotherapy-induced pain
T28	o 1523 1587	chemotherapy-induced peripheral neuropathic pain . Pain severity
T29	o 1617 1660	Pain Inventory-Short Form average pain item
T30	o 1684 1688	pain
T31	o 1840 1855	average pain of
T32	o 2000 2004	mean
T33	o 2023 2041	average pain score
T34	o 2231 2249	pain of any amount
T35	o 2305 2347	chemotherapy-induced peripheral neuropathy
T36	o 2441 2445	pain